Article

Investigational New Drugs

, Volume 3, Issue 2, pp 117-121

First online:

Evaluation of mitoxantrone cardiac toxicity by nuclear angiography and endomyocardial biopsy: an update

  • Robert S. BenjaminAffiliated withDepartment of Medical Oncology, University of Texas System Cancer Center, M.D. Anderson Hospital and Tumor Institute
  • , Sant P. ChawlaAffiliated withDepartment of Medical Oncology, University of Texas System Cancer Center, M.D. Anderson Hospital and Tumor Institute
  • , Michael S. EwerAffiliated withDepartment of Internal Medicine, University of Texas System Cancer Center, M.D. Anderson Hospital and Tumor Institute
  • , C. Humberto CarrascoAffiliated withDepartment of Diagnostic Radiology, University of Texas System Cancer Center, M.D. Anderson Hospital and Tumor Institute
  • , Bruce MackayAffiliated withDepartment of Pathology, University of Texas System Cancer Center, M.D. Anderson Hospital and Tumor Institute
  • , Frankie HolmesAffiliated withDepartment of Medical Oncology, University of Texas System Cancer Center, M.D. Anderson Hospital and Tumor Institute

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Summary

Sixty-six patients who underwent endomyocardial biopsy for detection of mitoxantrone (Novantrone®; dihydroxyanthracenedione) cardiac toxicity were evaluated. All but one had breast cancer, 29 had received prior doxorubicin and 29 of the 37 patients who had not had prior doxorubicin received it or another anthracycline subsequently. Endomyocardial biopsy was carried out initially after four courses of chemotherapy with increasing intervals thereafter. Although cardiac ejection fraction was determined before each course of chemotherapy, our data are limited to cardiac ejection fractions from our own institution which were repeated approximately every four courses. Endomyocardial biopsy changes consisting of dilatation of the sarcoplasmic reticulum with vacuole formation, and myofibrillar dropout are similar to the early changes of anthracycline cardiomyopathy.

While there was a slight suggestion of increasing biopsy grade with increasing mitoxantrone dose, no significant changes in cardiac ejection fraction could be associated, regardless of prior doxorubicin therapy. We concluded that mitoxantrone does show morphologic evidence of cardiac toxicity; however, the structural changes are minor and are haemodynamically insignificant. Determination of how much mitoxantrone treatment may contribute to the deterioration of pre-existing doxorubicin damage must await the outcome of longer follow-up.

Key words

mitoxantrone cardiotoxicity angiography endomyocardial biopsy